FDA Actions in 2026
Major actions the U.S. Food and Drug Administration has taken in 2026 on foods and food chemicals, dietary supplements, compounded drugs, plant medicines and psychedelics, and drug labels. Each page reports the action from the primary documents — the FDA announcement, the Federal Register notice, the order or letter itself — with what it did, what it did not do, and where it stands as of October 2026.
FDA Actions in 2026 (12)
In date order, oldest first. The stars rate each action's legal weight: ★★★★★ a final action that changes what is sold or labelled nationwide; ★★★★ a proposed rule or order, or a final action of narrower reach; ★★★ a formal safety review or a final guidance; ★★ a request for information or a public meeting.
FDA Food Dye Actions in 2026
2026: the FDA revoked Orange B, proposed revoking Citrus Red No. 2, approved beetroot red and widened spirulina extract, and relaxed “no artificial colors” claims.
Read the full action →FDA Safety Reassessments of BHA, BHT and ADA (2026)
2026: the FDA opened post-market safety reassessments of the preservatives BHA and BHT and the dough conditioner azodicarbonamide, and finalized its chemical-review framework.
Read the full action →FDA Approves New Menopausal Hormone Therapy Labels (2026)
February 2026: the FDA approved the first six hormone therapy labels without boxed-warning statements on heart disease, breast cancer and probable dementia.
Read the full action →FDA Public Meeting on What Counts as a Dietary Ingredient (2026)
March 2026: the FDA asked for public input on how the “dietary substance” category applies to fermentation-made, cell-cultured and recombinant supplement ingredients.
Read the full action →FDA Review of Compounded Peptides Including BPC-157 (2026)
2026: BPC-157 and other peptides left the FDA’s significant-safety-risk category; in July the FDA proposed not listing any of the seven it took to its advisory committee.
Read the full action →FDA Proposal on Compounded Semaglutide and Tirzepatide (2026)
April 2026: the FDA proposed keeping semaglutide, tirzepatide and liraglutide off the list outsourcing facilities may compound from bulk ingredients, finding no clinical need.
Read the full action →7-OH Kratom Products: The 2026 Scheduling Steps
July 2026: the DEA moved to place concentrated 7-OH in Schedule I, with HHS and FDA support; natural kratom leaf is not the target.
Read the full action →FDA Final Guidance on Psychedelic Drug Trials (2026)
July 2026: the FDA finalized its guidance on designing clinical trials of psychedelic drugs and held a public hearing on possible future therapeutic use.
Read the full action →FDA Proposal to Make GRAS Notices Mandatory (2026)
August 2026: the FDA proposes requiring companies to notify it whenever they conclude a food ingredient is GRAS; comments close December 9, 2026.
Read the full action →FDA Request for Input on Botanical Drugs (2026)
September 2026: the FDA asked for public input on obstacles to developing plant-based prescription drugs, from quality standards to study design; comments close November 3.
Read the full action →FDA Ibogaine Research Notice (2026)
October 2026: the FDA asks for public comment on how early clinical trials of ibogaine should be designed (comments through November 20, 2026).
Read the full action →FDA Final Rule on Salt Substitutes in Standardized Foods (2026)
October 2026: a final rule lets 139 standardized foods, from bread to cheddar cheese, replace some or all added salt with safe and suitable salt substitutes; effective December 14, 2026.
Read the full action →